Ninlaro® (ixazomib) is the first oral proteasome inhibitor approved by the FDA to treat myeloma. Ninlaro is the third drug in the proteasome inhibitor class that has been approved for myeloma. It is indicated for myeloma patients who have received at least one prior therapy.
Purchase this product
FREE